Form 4 for RCUS Arcus Biosciences, Inc.
Accepted 2025-09-05 00:00:00 ET · period of report 2025-09-05 · accession 0001771961-25-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-05 | 2025-09-05 | RCUS | Azoy Alexander | CAO | S - Sale | $11.88 | -1,579 | 30.2K | -5% | -$18.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-05 | S | D | 1,579 | $11.88 | 30,194 | D | — | — | (F2) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 6, 2025. (F1) Consists of 1,579 shares purchased on 5/30/2025 through the Company's Employee Stock Purchase Plan. (F3) The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.55 to $12.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |